AU2016277883B2 - PD-1-CD28 fusion proteins and their use in medicine - Google Patents

PD-1-CD28 fusion proteins and their use in medicine Download PDF

Info

Publication number
AU2016277883B2
AU2016277883B2 AU2016277883A AU2016277883A AU2016277883B2 AU 2016277883 B2 AU2016277883 B2 AU 2016277883B2 AU 2016277883 A AU2016277883 A AU 2016277883A AU 2016277883 A AU2016277883 A AU 2016277883A AU 2016277883 B2 AU2016277883 B2 AU 2016277883B2
Authority
AU
Australia
Prior art keywords
leu
pro
ser
ala
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016277883A
Other languages
English (en)
Other versions
AU2016277883A8 (en
AU2016277883A1 (en
Inventor
Stefan Endres
Sebastian KOBOLD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2016277883A1 publication Critical patent/AU2016277883A1/en
Publication of AU2016277883A8 publication Critical patent/AU2016277883A8/en
Application granted granted Critical
Publication of AU2016277883B2 publication Critical patent/AU2016277883B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2016277883A 2015-06-19 2016-06-20 PD-1-CD28 fusion proteins and their use in medicine Active AU2016277883B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15172913.4 2015-06-19
EP15172913 2015-06-19
PCT/EP2016/064195 WO2016203048A1 (en) 2015-06-19 2016-06-20 Pd-1-cd28 fusion proteins and their use in medicine

Publications (3)

Publication Number Publication Date
AU2016277883A1 AU2016277883A1 (en) 2018-01-18
AU2016277883A8 AU2016277883A8 (en) 2018-01-25
AU2016277883B2 true AU2016277883B2 (en) 2020-09-17

Family

ID=53476720

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016277883A Active AU2016277883B2 (en) 2015-06-19 2016-06-20 PD-1-CD28 fusion proteins and their use in medicine

Country Status (13)

Country Link
US (2) US11192935B2 (OSRAM)
EP (3) EP4349854A3 (OSRAM)
JP (3) JP7085988B2 (OSRAM)
CN (3) CN115925971A (OSRAM)
AU (1) AU2016277883B2 (OSRAM)
CA (1) CA2989949A1 (OSRAM)
DK (2) DK3909972T5 (OSRAM)
ES (2) ES2870174T3 (OSRAM)
FI (1) FI3909972T3 (OSRAM)
HU (1) HUE054201T2 (OSRAM)
PL (1) PL3310805T3 (OSRAM)
PT (1) PT3310805T (OSRAM)
WO (1) WO2016203048A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201908203SA (en) 2015-03-05 2019-10-30 Hutchinson Fred Cancer Res Immunomodulatory Fusion Proteins And Uses Thereof
DK3298033T4 (da) 2015-05-18 2023-10-02 Tcr2 Therapeutics Inc Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
CA2989949A1 (en) * 2015-06-19 2016-12-22 Sebastian KOBOLD Pd-1-cd28 fusion proteins and their use in medicine
KR20180038447A (ko) * 2015-06-29 2018-04-16 더 존스 홉킨스 유니버시티 면역 체크포인트 키메라 수용체 치료법
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
EP4286522A3 (en) * 2016-03-23 2024-02-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
CN107523545A (zh) * 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的杀伤性细胞及其用途
KR20190025855A (ko) * 2016-06-30 2019-03-12 에프. 호프만-라 로슈 아게 개선된 입양 t-세포 요법
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2017382902A1 (en) * 2016-12-21 2019-07-18 TCR2 Therapeutics Inc. Engineered T cells for the treatment of cancer
US11535662B2 (en) * 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2018170475A1 (en) 2017-03-17 2018-09-20 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
EP3762410A4 (en) * 2018-03-06 2022-04-06 The Trustees of the University of Pennsylvania CHEMICAL PROSTATE MEMBRANE SPECIFIC ANTIGEN SPECIFIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
CN108727504B (zh) * 2018-04-16 2021-08-27 泉州向日葵生物科技有限公司 一种ifn与抗pd-l1抗体的融合蛋白及其应用
CN111606999B (zh) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用
JP7654557B2 (ja) * 2019-03-27 2025-04-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法
CN115298208A (zh) * 2019-07-19 2022-11-04 纪念斯隆-凯特琳癌症中心 免疫治疗用融合多肽
CN113832111A (zh) * 2020-06-23 2021-12-24 南京大学 一种类外泌体技术用于制备新型溶瘤病毒的方法
CN113832114A (zh) * 2020-06-23 2021-12-24 南京大学 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用
EP4305174A4 (en) * 2021-03-10 2025-04-30 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University REPORTER CELLS EXPRESSING CHIMERIC POLYPEPTIDES TO DETERMINE THE PRESENCE AND/OR ACTIVITY OF IMMUNE CHECKPOINT MOLECULES
CN115197314B (zh) * 2021-04-11 2025-08-19 中国科学院分子细胞科学卓越创新中心 一种pd1变体及其用途
US20240252613A1 (en) * 2021-05-20 2024-08-01 Achelois Biopharma, Inc. Immune checkpoint multivalent particles compositions and methods of use
WO2023235479A1 (en) * 2022-06-02 2023-12-07 TCR2 Therapeutics Inc. Compositions and methods for treating cancer
WO2024107577A2 (en) * 2022-11-14 2024-05-23 Achelois Biopharma, Inc. Immune checkpoint multivalent particles compositions and methods of use
WO2025212859A1 (en) * 2024-04-03 2025-10-09 Solid Biosciences, Inc. Methods and constructs for increasing solid organ transplant survival

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019615A2 (en) * 2011-07-29 2013-02-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
US20140242049A1 (en) * 2011-10-26 2014-08-28 National Cancer Center Mutant ctla4 gene transfected t cell and composition including same for anticancer immunotherapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19822115B4 (de) 1998-05-08 2004-04-08 Heinrich-Pette-Institut Retrovirale Gentransfervektoren
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
US20110280894A1 (en) 2008-07-31 2011-11-17 Angela Krackhardt Her2/neu specific t cell receptors
ZA200807283B (en) 2008-08-22 2009-10-28 Mechlift Invest Pty Ltd Data unit for a bin lifting device
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PL2694549T3 (pl) 2011-04-08 2019-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeryczne receptory antygenowe anty-wariant III receptora czynnika wzrostu naskórka i ich zastosowanie do leczenia raka
BR112014008849A2 (pt) 2011-10-20 2017-09-12 Us Health receptores quiméricos de antígeno anti-cd22
WO2013062365A2 (ko) 2011-10-26 2013-05-02 국립암센터 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
EP2828290B1 (en) 2012-03-23 2018-08-15 The United States of America, represented by the Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
KR102086874B1 (ko) 2012-04-11 2020-03-10 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
DK3039040T3 (da) 2013-08-26 2022-02-07 Hinrich Abken Kimær anti cd30-antigenreceptor og anvendelse deraf
SG11201704519YA (en) 2014-12-02 2017-07-28 Roger Williams Hospital Methods and compositons for treating cancer
CA2989949A1 (en) 2015-06-19 2016-12-22 Sebastian KOBOLD Pd-1-cd28 fusion proteins and their use in medicine
CN111051349A (zh) 2017-09-06 2020-04-21 弗雷德哈钦森癌症研究中心 Strep-tag特异性嵌合受体及其用途
CN110951718B (zh) * 2019-12-02 2022-09-30 吉林凯莱英医药化学有限公司 共固定化酶、其制备方法及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019615A2 (en) * 2011-07-29 2013-02-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
US20140242049A1 (en) * 2011-10-26 2014-08-28 National Cancer Center Mutant ctla4 gene transfected t cell and composition including same for anticancer immunotherapy

Also Published As

Publication number Publication date
ES2976647T3 (es) 2024-08-06
EP3310805A1 (en) 2018-04-25
AU2016277883A8 (en) 2018-01-25
EP3310805B1 (en) 2021-02-17
EP4349854A2 (en) 2024-04-10
DK3310805T3 (da) 2021-05-03
JP2024073636A (ja) 2024-05-29
CN115925971A (zh) 2023-04-07
US20190010207A1 (en) 2019-01-10
PL3310805T3 (pl) 2021-08-23
WO2016203048A1 (en) 2016-12-22
EP3909972B1 (en) 2024-02-14
JP2018518990A (ja) 2018-07-19
EP4349854A3 (en) 2024-07-10
DK3909972T3 (da) 2024-04-29
JP7460675B2 (ja) 2024-04-02
EP3909972A1 (en) 2021-11-17
FI3909972T3 (fi) 2024-05-03
HUE054201T2 (hu) 2021-08-30
AU2016277883A1 (en) 2018-01-18
US11192935B2 (en) 2021-12-07
CN108026151A (zh) 2018-05-11
CN108026151B (zh) 2022-07-15
US20220169699A1 (en) 2022-06-02
CA2989949A1 (en) 2016-12-22
DK3909972T5 (da) 2024-08-05
CN115927474A (zh) 2023-04-07
JP7085988B2 (ja) 2022-06-17
PT3310805T (pt) 2021-05-19
JP2022084787A (ja) 2022-06-07
ES2870174T3 (es) 2021-10-26

Similar Documents

Publication Publication Date Title
JP7460675B2 (ja) Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
AU2017205637B2 (en) Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors
EP3433269B1 (en) Fusion proteins of pd-1 and 4-1bb
KR20210150440A (ko) Mage a4 t 세포 수용체
CN110330567A (zh) 双特异性嵌合抗原受体t细胞，其制备方法和应用
CN108137670A (zh) Ny-eso-1特异性tcr及其使用方法
HK1251862A1 (zh) 治疗癌症的方法和组合物
EP3099708B1 (en) Methods and compositions for producing a cell expressing a t cell receptor
AU2016336868B2 (en) CXCR6-transduced T cells for targeted tumor therapy
JP2025505546A (ja) キメラｉｌｔ受容体組成物及び方法
KR20240005865A (ko) Prame 특이적 t 세포 수용체 및 키메라 공동 자극 수용체의 조합
US20220211831A1 (en) Siglec-based chimeric polypeptides and uses thereof
US20250108069A1 (en) Chimeric adaptor polypeptides
HK40109405A (en) Pd1-cd28 fusion proteins and their use in medicine
HK40064520B (en) Pd1-cd28 fusion proteins and their use in medicine
HK40064520A (en) Pd1-cd28 fusion proteins and their use in medicine
KR20240095172A (ko) 항원 특이적 t 세포 수용체 및 키메라 공동자극 수용체의 조합
JP2022554349A (ja) Ｈｌａ拘束性ｈｏｒｍａｄ１ ｔ細胞受容体およびその使用

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 32 , NO 2 , PAGE(S) 263 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SEBASTIEN KOBOLD; STEFAN ENDRES, APPLICATION NO. 2016277883, UNDER INID (71) CORRECT THE APPLICANT NAME TO SEBASTIAN KOBOLD

FGA Letters patent sealed or granted (standard patent)